Knowledge and Attitudes of Indonesian General Practitioners Towards the Isoniazid Preventive Therapy Program in Indonesia

Overview

Journal J Prev Med Public Health

Specialty Public Health

Date 2022 Oct 14

PMID 36229905

Authors

Wira Winardi

Widhy Yudistira Nalapraya

Sarifuddin Sarifuddin

Samsul Anwar

Amanda Yufika

Adityo Wibowo

Iziddin Fadhil

Hendra Wahyuni Ms

Yunita Arliny

Dewi Behtri Yanifitri

Teuku Zulfikar

Harapan Harapan

Affiliations

Soon will be listed here.

Abstract

Objectives: The Indonesian Ministry of Health launched isoniazid preventive therapy (IPT) in 2016, with general practitioners (GPs) at the frontline of this program. However, the extent to which GPs have internalized this program remains uncertain. The aim of this study was to identify the knowledge and attitudes of GPs towards the IPT program in Indonesia.

Methods: This study used an online, self-administered questionnaire distributed via e-mail and social messaging services. A logistic regression model was employed to identify the explanatory variables influencing the level of knowledge and attitudes toward IPT among GPs in Indonesia. An empirical analysis was conducted separately for each response variable (knowledge and attitudes).

Results: Of the 418 respondents, 128 (30.6%) had a good knowledge of IPT. Working at a public hospital was the only variable associated with good knowledge, with an adjusted odds ratio (aOR) of 1.69 (95% confidence interval [CI], 1.02 to 2.81). Furthermore, 279 respondents (66.7%) had favorable attitudes toward IPT. In the adjusted logistic regression analysis, good knowledge (aOR, 0.55; 95% CI, 0.34 to 0.89), 1-5 years of work experience (aOR, 2.09; 95% CI, 1.21 to 3.60), and having experienced IPT training (aOR, 0.48; 95% CI, 0.25 to 0.93), were significantly associated with favorable attitudes.

Conclusions: In general, GPs in Indonesia had favorable attitudes toward IPT. However, their knowledge of IPT was limited. GPs are an essential element of the IPT program in the country, and therefore, adequate information dissemination to improve their understanding is critical for the long-term viability and quality of the IPT program in Indonesia.

References

Chakaya J, Petersen E, Nantanda R, Mungai B, Migliori G, Amanullah F . The WHO Global Tuberculosis 2021 Report - not so good news and turning the tide back to End TB. Int J Infect Dis. 2022; 124 Suppl 1:S26-S29. PMC: 8934249. DOI: 10.1016/j.ijid.2022.03.011. View

Ayele H, van Mourik M, Bonten M . Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia. Int J Tuberc Lung Dis. 2016; 20(10):1342-1347. DOI: 10.5588/ijtld.15.0805. View

Houben R, Dodd P . The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med. 2016; 13(10):e1002152. PMC: 5079585. DOI: 10.1371/journal.pmed.1002152. View

. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017; 18(3):261-284. PMC: 5831985. DOI: 10.1016/S1473-3099(17)30703-X. View

Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P . Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts. Int J Infect Dis. 2021; 113 Suppl 1:S7-S12. PMC: 8433257. DOI: 10.1016/j.ijid.2021.02.107. View

Zumla A, Nahid P, Cole S . Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013; 12(5):388-404. DOI: 10.1038/nrd4001. View

Mandal S, Bhatia V, Sharma M, Mandal P, Arinaminpathy N . The potential impact of preventive therapy against tuberculosis in the WHO South-East Asian Region: a modelling approach. BMC Med. 2020; 18(1):163. PMC: 7369473. DOI: 10.1186/s12916-020-01651-5. View

Huang C, Becerra M, Calderon R, Contreras C, Galea J, Grandjean L . Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2020; 202(8):1159-1168. PMC: 7560814. DOI: 10.1164/rccm.201908-1576OC. View

Ross J, Badje A, Rangaka M, Walker A, Shapiro A, Thomas K . Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV. 2021; 8(1):e8-e15. PMC: 7875572. DOI: 10.1016/S2352-3018(20)30299-X. View

10.

Surya A, Setyaningsih B, Nasution H, Gita Parwati C, Yuzwar Y, Osberg M . Quality Tuberculosis Care in Indonesia: Using Patient Pathway Analysis to Optimize Public-Private Collaboration. J Infect Dis. 2017; 216(suppl_7):S724-S732. PMC: 5853837. DOI: 10.1093/infdis/jix379. View

11.

MacNeil A, Glaziou P, Sismanidis C, Date A, Maloney S, Floyd K . Global Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets - Worldwide, 2018. MMWR Morb Mortal Wkly Rep. 2020; 69(11):281-285. PMC: 7739980. DOI: 10.15585/mmwr.mm6911a2. View

12.

Reviono R, Setianingsih W, Damayanti K, Ekasari R . The dynamic of tuberculosis case finding in the era of the public-private mix strategy for tuberculosis control in Central Java, Indonesia. Glob Health Action. 2017; 10(1):1353777. PMC: 5964974. DOI: 10.1080/16549716.2017.1353777. View

13.

Burke R, Nliwasa M, Feasey H, Chaisson L, Golub J, Naufal F . Community-based active case-finding interventions for tuberculosis: a systematic review. Lancet Public Health. 2021; 6(5):e283-e299. PMC: 8082281. DOI: 10.1016/S2468-2667(21)00033-5. View

14.

van Halsema C, Fielding K, Chihota V, Russell E, Lewis J, Churchyard G . Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS. 2010; 24(7):1051-5. DOI: 10.1097/QAD.0b013e32833849df. View

15.

Collins D, Hafidz F, Mustikawati D . The economic burden of tuberculosis in Indonesia. Int J Tuberc Lung Dis. 2017; 21(9):1041-1048. DOI: 10.5588/ijtld.16.0898. View

16.

Durovni B, Cavalcante S, Saraceni V, Vellozo V, Israel G, King B . The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS. 2010; 24 Suppl 5:S49-56. PMC: 3066070. DOI: 10.1097/01.aids.0000391022.95412.a6. View

17.

Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E . Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health. 2016; 16(1):840. PMC: 4992328. DOI: 10.1186/s12889-016-3525-8. View

18.

Ayele H, van Mourik M, Debray T, Bonten M . Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One. 2015; 10(11):e0142290. PMC: 4638336. DOI: 10.1371/journal.pone.0142290. View

19.

Bateman C . Doctor IPT ignorance contributing to TB epidemic--study. S Afr Med J. 2011; 101(2):88, 90. DOI: 10.7196/samj.4734. View

20.

Smieja M, Marchetti C, Cook D, Smaill F . Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000; (2):CD001363. PMC: 6532737. DOI: 10.1002/14651858.CD001363. View